Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the treatment of patients with untreated symmetric proliferative diabetic retinopathy.
Epistemonikos ID: ae230c40459a559b6a9c4dd07711f88b00864426
First added on: May 04, 2024